4//SEC Filing
Mazumdar-Shaw Kiran 4
Accession 0000950170-24-106866
CIK 0002023658other
Filed
Sep 15, 8:00 PM ET
Accepted
Sep 16, 4:35 PM ET
Size
22.9 KB
Accession
0000950170-24-106866
Insider Transaction Report
Form 4
Mazumdar-Shaw Kiran
Director10% Owner
Transactions
- Conversion
Common Stock
2024-09-16+432,736→ 432,736 total(indirect: By Carica Investments) - Conversion
Common Stock
2024-09-16+4,327,365→ 4,443,122 total(indirect: By Biocon Limited) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−3,000,000→ 0 total(indirect: By Glentech International)→ Common Stock (324,552 underlying) - Conversion
Common Stock
2024-09-16+1,080,775→ 1,080,775 total(indirect: By Biocon Pharma Inc.) - Conversion
Common Stock
2024-09-16+324,552→ 324,552 total(indirect: By Glentech International) - Award
Stock Option (Right to Buy)
2024-09-12+23,746→ 23,746 totalExercise: $18.00Exp: 2034-09-12→ Common Stock (23,746 underlying) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−40,000,000→ 0 total(indirect: By Biocon Limited)→ Common Stock (4,327,365 underlying) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−9,990,144→ 0 total(indirect: By Biocon Pharma Inc.)→ Common Stock (1,080,775 underlying) - Conversion
Series Seed Redeemable Convertible Preferred Stock
2024-09-16−4,000,000→ 0 total(indirect: By Carica Investments)→ Common Stock (432,736 underlying)
Footnotes (6)
- [F1]Upon the closing of the Issuer's initial public offering, each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") automatically converted into Common Stock on a 9.2435-to-one basis without payment of consideration. The Preferred Stock had no expiration date.
- [F2]Shares held by Biocon Limited ("Biocon Ltd"). The Reporting Person is the managing member of Biocon Ltd and disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]Shares held by Biocon Pharma Inc. ("Biocon Pharma"). The Reporting Person is the managing member of Biocon Pharma and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F4]Shares held by Glentech International ("Glentech"). The Reporting Person is the managing member of Glentech and disclaims beneficial ownership of such shares for purposes of Section 16 of Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F5]Shares held by Carica Investments ("Carica"). The Reporting Person is the managing partner of Carica and disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her pecuniary interest therein, if any. This report shall not be deemed an admission that she is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F6]The shares underlying this option shall vest upon the earlier of (i) August 16, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.
Documents
Issuer
Bicara Therapeutics Inc.
CIK 0002023658
Entity typeother
Related Parties
1- filerCIK 0002034672
Filing Metadata
- Form type
- 4
- Filed
- Sep 15, 8:00 PM ET
- Accepted
- Sep 16, 4:35 PM ET
- Size
- 22.9 KB